Theravance Biopharma (NASDAQ:TBPH) Major Shareholder Eli Samaha Sells 25,027 Shares

Theravance Biopharma, Inc. (NASDAQ:TBPH) major shareholder Eli Samaha sold 25,027 shares of Theravance Biopharma stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $17.13, for a total value of $428,712.51. Following the completion of the sale, the insider owned 9,212,252 shares of the company’s stock, valued at $157,805,876.76. The trade was a 0.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Eli Samaha also recently made the following trade(s):

• On Wednesday, July 1st, Eli Samaha sold 37,799 shares of Theravance Biopharma stock. The stock was sold at an average price of $17.00, for a total value of $642,583.00.
• On Monday, June 29th, Eli Samaha sold 273,871 shares of Theravance Biopharma stock. The shares were sold at an average price of $17.23, for a total transaction of $4,718,797.33.

Theravance Biopharma Stock Down 0.1%

Shares of NASDAQ TBPH opened at $16.98 on Thursday. The firm’s 50-day moving average price is $16.56 and its 200-day moving average price is $17.29. Theravance Biopharma, Inc. has a 52-week low of $10.82 and a 52-week high of $21.03. The company has a market cap of $875.37 million, a PE ratio of 7.72 and a beta of 0.17.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings data on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) earnings per share for the quarter. The company had revenue of $17.70 million for the quarter. Theravance Biopharma had a net margin of 104.34% and a return on equity of 18.84%. As a group, equities research analysts anticipate that Theravance Biopharma, Inc. will post 1.54 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently weighed in on TBPH. B. Riley Financial increased their price target on Theravance Biopharma from $14.00 to $17.00 and gave the company a “neutral” rating in a report on Tuesday, April 7th. Weiss Ratings lowered shares of Theravance Biopharma from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday, May 27th. Wall Street Zen cut shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. JonesTrading downgraded shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Monday. Finally, Oppenheimer cut shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating in a research note on Thursday, March 5th. One equities research analyst has rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat.com, Theravance Biopharma presently has an average rating of “Hold” and a consensus price target of $21.40.

Institutional Trading of Theravance Biopharma

A number of hedge funds and other institutional investors have recently modified their holdings of TBPH. Quarry LP bought a new stake in Theravance Biopharma during the third quarter valued at about $26,000. Caitong International Asset Management Co. Ltd boosted its stake in shares of Theravance Biopharma by 107.4% in the third quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock worth $40,000 after acquiring an additional 1,411 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Theravance Biopharma by 26.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company’s stock worth $46,000 after acquiring an additional 515 shares during the period. Tower Research Capital LLC TRC grew its position in shares of Theravance Biopharma by 18.5% during the second quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 781 shares in the last quarter. Finally, CIBC Private Wealth Group LLC raised its stake in Theravance Biopharma by 20,269.6% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock valued at $68,000 after purchasing an additional 4,662 shares during the period. 99.10% of the stock is owned by hedge funds and other institutional investors.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.